Warning: The NCBI web site requires JavaScript to function. more...
Non-pharmaceutical prevention of hip fractures - a cost-effectiveness analysis of a community-based elderly safety promotion program in Sweden.
Johansson P, Sadigh S, Tillgren P, Rehnberg C.
Cost Eff Resour Alloc. 2008 May 30;6:11.
Related citations
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
Int J Clin Pharmacol Res. 2004;24(1):1-10.
Statistical modelling needed to find the effects from a community-based elderly safety promotion program.
Johansson PM, de Leon AP, Sadigh S, Tillgren PE, Rehnberg C.
Eur J Public Health. 2009 Jan;19(1):100-5. Epub 2008 Nov 7.
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.
Health Technol Assess. 2005 Jun;9(22):1-160. Review.
Impact of a community-based osteoporosis and fall prevention program on fracture incidence.
Grahn Kronhed AC, Blomberg C, Karlsson N, Löfman O, Timpka T, Möller M.
Osteoporos Int. 2005 Jun;16(6):700-6. Epub 2004 Sep 30.
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Brecht JG, Kruse HP, Felsenberg D, Möhrke W, Oestreich A, Huppertz E.
Int J Clin Pharmacol Res. 2003;23(4):93-105.
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.
Borgström F, Jönsson B, Ström O, Kanis JA.
Osteoporos Int. 2006 Dec;17(12):1781-93. Epub 2006 Sep 29.
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Borgström F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jönsson B, Kanis JA.
Osteoporos Int. 2006;17(7):996-1007. Epub 2006 Mar 29.
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B; LIFE Study Group.
J Hypertens. 2005 Jul;23(7):1425-31.
Participation, resource mobilization and financial incentives in community-based health promotion: an economic evaluation perspective from Sweden.
Johansson PM, Eriksson LS, Sadigh S, Rehnberg C, Tillgren PE.
Health Promot Int. 2009 Jun;24(2):177-84. Epub 2009 Mar 24.
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B.
Pharmacoeconomics. 2004;22(17):1153-65.
A cost-effectiveness analysis of a community-based diabetes prevention program in Sweden.
Johansson P, Ostenson CG, Hilding AM, Andersson C, Rehnberg C, Tillgren P.
Int J Technol Assess Health Care. 2009 Jul;25(3):350-8.
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.
Pharmacoeconomics. 2008;26(4):311-28.
The socioeconomic burden of fractures: today and in the 21st century.
Johnell O.
Am J Med. 1997 Aug 18;103(2A):20S-25S; discussion 25S-26S. Review.
Costs and quality of life associated with osteoporosis-related fractures in Sweden.
Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjö K, Thorngren KG, Sernbo I, Rehnberg C, Jönsson B.
Osteoporos Int. 2006;17(5):637-50. Epub 2005 Nov 9.
Costs and health effects of osteoporotic fractures.
Chrischilles E, Shireman T, Wallace R.
Bone. 1994 Jul-Aug;15(4):377-86.
Cost-effectiveness of fracture prevention in established osteoporosis.
Jönsson B, Christiansen C, Johnell O, Hedbrandt J.
Osteoporos Int. 1995 Mar;5(2):136-42.
The societal burden of osteoporosis in Sweden.
Borgström F, Sobocki P, Ström O, Jönsson B.
Bone. 2007 Jun;40(6):1602-9. Epub 2007 Mar 7.
Jönsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G.
Scand J Rheumatol Suppl. 1996;103:30-8; discussion 39-40.
A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA.
Scand J Public Health. 2005;33(5):343-52.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on